Prolonged immunosuppression in solid organ transplant recipients has been considered a risk for developing opportunistic infections and malignancies. Acute leukemia is a rare complication. We report a case of acute promyelocytic leukemia (APL) (FAB M3) after cadaveric renal transplant for focal segmental glomerulosclerosis in a 24-year-old woman. Her immunosuppressive therapy included tacrolimus, mycophenolate mofetil, and prednisone. Approximately 2 years after transplant, she became pancytopenic, prompting administration of filgrastim. A few doses caused a markedly increased blast count, resulting in a diagnosis of APL. She was successfully treated with all-trans -retinoic acid and arsenic trioxide. Myeloproliferative neoplasms after organ transplant or due to filgrastim are rare. I mmunosuppressants off er prolonged survival and improve the quality of life in solid organ transplant recipients. However, long-term administration of immunosuppressants can increase the risk for opportunistic infections and malignancies such as lymphoproliferative disorders, epithelial tumors, and therapy-related myeloid neoplasms ( 1, 2 ) . Granulocyte colony-stimulating factors (G-CSF), like fi lgrastim, are eff ective in increasing white blood cell counts and thus help protect against opportunistic infections ( 3 ) . Eff ects of G-CSF are transient and rarely result in markedly increased numbers of blasts or leukemia. We present the case of a 24-year-old female renal transplant patient under chronic immunosuppressive therapy who was diagnosed with acute promyelocytic leukemia (APL) (FAB M3) after a few doses of fi lgrastim were given for newonset neutropenia.
CASE REPORT
In October 2013, a 24-year-old woman received a cadaveric right kidney transplant for focal segmental glomerulosclerosis. Her posttransplant immunosuppressant regimen included tacrolimus (5 mg twice daily), mycophenolate mofetil (1080 mg twice daily), and prednisone (10 mg twice daily). A few months after transplant, she was admitted for recurrent urinary tract infections and elevated white blood cell (WBC) counts and was given long-term sulfamethoxazole/ trimethoprim (Bactrim). A renal biopsy performed 8 months after transplant showed rejection, and her serum tacrolimus Acute promyelocytic leukemia after renal transplant and filgrastim treatment for neutropenia Jaime A. Campbell , MD, MS, and John R. Krause , MD level had risen to 14.0 ng/mL. She was given additional doses of methylprednisolone, and tacrolimus was decreased to 3 mg twice daily. At a subsequent hospital admission 1 year later for a urinary tract infection, she was found to have Clostridium diffi cile, sepsis, and a brief upper gastrointestinal bleed diagnosed as a Mallory-Weiss tear. She was pancytopenic compared to her baseline values (WBC 0.5 K/μL, hemoglobin 7.7 g/dL, hematocrit 21.6%, platelets 47 K/μL), thought to be secondary to her sepsis and marrow suppression from long-term administration of Bactrim and mycophenolate (at a reported dose of 720 mg twice daily). Bactrim and mycophenolate were discontinued, while tacrolimus (4 mg twice daily) and prednisone (10 mg once daily) were continued. Filgrastim (Neupogen 480 mcg subcutaneous once daily) was administered to increase WBC recovery. Th ere was an appropriate response in her WBC count with resulting bandemia, followed by an unexpected marked elevation in blast count after three doses.
Evaluation of the peripheral blood showed marked pancytopenia and 27% circulating immature cells with convoluted and bilobed nuclei, nucleoli, cytoplasmic blebbing, and occasional cytoplasmic granules (Figure 1a) . Flow cytometry of the peripheral blood showed 47% immature cells characteristic of promyelocytes. Fluorescence in situ hybridization was positive for the PML/RARα t(15;17) fusion transcripts (Figure 1b) , diagnostic for acute promyelocytic leukemia. No other cytogenetic abnormalities were detected.
Evaluation of the bone marrow revealed 85% cellularity (Figure 1c ) with 55% immature cells positive for myeloperoxidase and partially positive for CD34, granulocyte maturation arrest, and decreased numbers of megakaryocytes and erythroid precursors. Flow cytometry of the bone marrow detected 55% small to medium-sized immature cells expressing similar markers as in the peripheral blood. Overall, the fi ndings were diagnostic for APL. Th e patient was started on all-trans -retinoic acid and arsenic trioxide, which allowed for current remission.
DISCUSSION
Our patient presented with pancytopenia; suspicion for a myelodysplastic disorder (MDS) or posttransplant lymphoproliferative disease was low due to her young age and lack of adenopathy or other symptoms. Acute myeloid leukemia as a posttransplant complication is rare (0.2%-2.5%) ( 1 ) and was suspected only after G-CSF treatment resulted in the proliferation of blast-like cells in the circulation. Th is patient most likely developed a therapy-related myeloid neoplasm as a late complication of chronic immunosuppression administered for renal transplant maintenance.
G-CSF is a hematopoietic cytokine produced by monocytes, fi broblasts, and endothelial cells whose role is to regulate the production, diff erentiation, and activation of neutrophils ( 3, 4 ) . It stimulates the development of primitive hematopoietic stem cells and the release of CD34 + progenitors from the marrow into the circulation. As such, it is helpful in reducing febrile neutropenia in immunocompromised patients to protect against opportunistic infections ( 5 ) . Transient eff ects of G-CSF include a shift towards earlier granulocyte progenitor cells (left shift) with the appearance of promyelocytes and myeloblasts‚ Döhle bodies‚ increased granulocyte granulation‚ as well as hypersegmented neutrophils. Th e peak incidence of CD34 + cells is in the range of 15-to 35-fold and usually occurs on day 5 ( 4 ).
Th ere is controversy regarding G-CSF's role in enhancing or accelerating leukemogenesis and causing MDS or a myeloproliferative neoplasm. Patients receiving long-term treatment or those already at risk of a secondary MDS and/or acute myeloid leukemia, such as those with severe congenital neutropenia (Kostmann's syndrome), have increased susceptibility to develop MDS and AML. Th is is believed to be due to mutations in the G-CSF receptor gene and appears to increase with the duration of G-CSF therapy ( 3, 4, 6 ) , with a cumulative incidence of 36% after 12 years of treatment ( 4 ) . Th e eff ect of G-CSF on the development of abnormal cytogenetics and the eff ect of continued G-CSF administration in patients with abnormal cytogenetics or MDS are unknown. Although it is unlikely that fi lgrastim caused APL in our patient, it is conceivable that it augmented proliferation of the preexisting clone. APL cells are exquisitely responsive to G-CSF because they highly express the G-CSF receptor compared with leukemic cells in other types of AML ( 7 ) .
Chronic immunosuppression for renal transplant maintenance likely played a role in the pathogenesis of leukemia in this patient. Th erapy-related APLs have been reported in chronically immunosuppressed patients, including a patient with Crohn's disease and liver and kidney transplant recipients (8) (9) (10) (11) (12) . Cytotoxic antimetabolites such as mycophenolate, used in many immunosuppressive regimens, have been implicated in the development of secondary APL following renal transplantation ( 1, 8, 10 ) . Th ese secondary APLs seem to have similar clinical, morphologic, and pathologic features as de novo APL in the cases reported, including a good prognosis ( 8 ) . 
